Answers are grounded in this paper and cite their sources.
This review explores the development and phase III trial failures of oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban, providing insights into their lack of clinical benefit.
A number of studies have reported on the successful use of intravenous glycoprotein IIb/IIIa receptor antagonists in patients with unstable angina or undergoing percutaneous interventions. The promise of interrupting the aggregation of platelets in the setting of unstable plaques on a chronic basis had led to the evaluation of several oral agents for longer-term administration. The development program of two of these agents, xemilofiban and orbofiban, will be reviewed and evaluated to understand the selection process of therapeutic targets for use based upon complex pharmacokinetic and pharmacodynamic responses. A review of the pivotal phase III trial results will also be provided along with insights into the potential reasons for the lack of significant benefit shown with these agents to date.
No takes yet. Share an insight, caveat, or question.
Anders et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: